A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
about
Acute promyelocytic leukemia: where did we start, where are we now, and the futureTreatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patientsSuccessful management of chronic refractory immune thrombocytopenia with laparoscopic splenectomy in a patient with acute promyelocytic leukemiaCuring all patients with acute promyelocytic leukemia: are we there yet?Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.Long FLT3 internal tandem duplications and reduced PML-RARĪ± expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.Treatment advances have not improved the early death rate in acute promyelocytic leukemia.Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA GroupExpression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell countsPrognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia.Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid eraNewly diagnosed acute promyelocytic leukemiaResults of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaAbsolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemiaSolid tumor differentiation therapy - is it possible?Trisomy 11 as an additional chromosome alteration in a child with acute promyelocytic leukemia with poor prognosis.Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groupsEmerging new approaches for the treatment of acute promyelocytic leukemia.Molecular Monitoring as a Path to Cure Acute Promyelocytic LeukemiaEarly death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acidTherapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia.Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the LiteratureSurvival and treatment response in adults with acute promyelocytic leukemia treated with a modified International Consortium on Acute Promyelocytic Leukemia protocol.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Provocative pearls in diagnosing and treating acute promyelocytic leukemia.Contemporary treatment of APLManagement of acute promyelocytic leukemia in the elderly.Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia.Evaluation of the efficacy of maintenance therapy for low-to-intermediate-risk acute promyelocytic leukemia in molecular remission: A retrospective single-institution study.Outcome of childhood acute promyelocytic leukemia treated using a modified AIDA protocol.High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature.
P2860
Q26830385-7A915126-6DE9-4153-86FF-AA009D1D6A09Q27851636-A82132C9-5AA5-46E2-B69D-1768A108CC59Q33412672-AEC69A57-1854-4423-9190-F156379B1D5DQ33613426-036C8965-673C-4592-8931-B12A7A47D8C4Q33707423-B79DE5EE-9F58-4B9E-9291-62D2C497EEFAQ33829079-F7F8B3E0-D704-4FB0-B3FF-9E450D278909Q34223654-9A173513-F073-4942-83ED-8A4DA0C86ECBQ34310859-EDC5B5EC-29F0-4B48-8C47-B69B137C629DQ34541742-4C35D2BB-CE85-4CC7-AA15-3DE0C1E0AA49Q35051695-BC416878-CC4D-4199-AA43-B5944854AC42Q35265901-820EC88B-F316-485A-8F11-2505A3FADE05Q35290367-12CEDD37-7997-4AF7-97B0-6EC942377B95Q35640734-C3B4A46D-5FBF-4126-B02A-2DB0E805C72EQ35640773-B55215F6-021E-429E-B151-4B22602F165EQ35717816-389D0736-BD48-4FBD-B1F9-87EF0839469FQ35955272-5BD46F76-0375-490F-A955-7F2B2A443A7DQ36071880-AC966F04-08EC-4062-9370-16C68C20F1FFQ36248003-06C206FA-6B7B-4543-BA10-D6FFA00F6C53Q36579091-BA2693F6-05AC-44D4-8107-6CD51A65CCA1Q36612619-6F758C27-E779-4EAE-B891-9E71711ED96DQ36816685-E53DD59C-B6D9-4DEE-B654-D39B20AD1790Q37216174-4D01EC8E-581B-4F2F-903B-53BFC158B822Q37271941-B74900EC-5D4A-46A0-8451-223E14D329EDQ37397791-D13170EC-C919-4F34-90E0-B2337ACAFEA8Q37418961-337D6EFE-D1DE-4B32-92A9-86587E23EB17Q37429222-A8616DD6-048B-4C16-AA1A-C0B52AD814E0Q37712353-F7FF743C-1B09-4C56-BB34-3F61FB9DE103Q38034229-EC5E6963-ADD7-4607-B035-3C9753219B5AQ38197074-46559669-7357-4F9A-BFB0-C673D5540460Q39368616-D01BDD12-DF00-45C6-9884-5B0E8E97832DQ42137618-132D1080-1190-477D-880F-BF5555AEA158Q42259192-289D3107-E825-49AB-8467-5E68A06A3772Q42284173-A6707E0E-DF64-4DBC-A672-D471F883A089Q42328350-93B5D075-810C-4693-93E3-0C969DAF9B01Q55027010-9B11073E-1A17-4CD3-BC09-1761A73497D6
P2860
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
description
1999 nĆ® lÅ«n-bĆ»n
@nan
1999 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕøÕµÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
1999 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ¶ÕøÕµÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
1999幓ć®č«ę
@ja
1999幓č«ę
@yue
1999幓č«ę
@zh-hant
1999幓č«ę
@zh-hk
1999幓č«ę
@zh-mo
1999幓č«ę
@zh-tw
1999幓č®ŗę
@wuu
name
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@ast
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@en
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@nl
type
label
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@ast
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@en
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@nl
prefLabel
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@ast
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@en
A modified AIDA protocol with ...... cytic leukemia. PETHEMA group.
@nl
P2093
P1433
P1476
A modified AIDA protocol with ...... ocytic leukemia. PETHEMA group
@en
P2093
BarragƔn E
Bornstein R
Calasanz MJ
ChillĆ³n C
DĆaz-Mediavilla J
P304
P407
P577
1999-11-01T00:00:00Z